China's Burning Rock Biotech Q4 net loss narrows as costs fall

Reuters03-12 19:15

China's <a href="https://laohu8.com/S/BNR">Burning Rock Biotech</a> Q4 net loss narrows as costs fall

Overview

China precision oncology firm's Q4 revenue was stable year-over-year at RMB126.3 mln
Gross profit and gross margin rose, supported by lower costs and higher-margin mix
Net loss narrowed sharply on lower operating expenses from cost controls and headcount reduction

Outlook

Company did not provide specific guidance for future periods

Result Drivers

CENTRAL LAB GROWTH - Revenue from central laboratory business rose 12.1% on higher CanCatch test volumes
IN-HOSPITAL EXPANSION - In-hospital business revenue rose 17.3% due to increased sales volume from existing and new partner hospitals
PHARMA SERVICES DECLINE - Pharma R&D services revenue fell 27.7% due to decreased testing services for pharma customers from timing of lumpy projects

Company press release: ID:nGNX6VPFB4

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue		RMB 126.30 mln
Q4 Net Income		-RMB 15.40 mln
Q4 Adjusted Gross Margin		80.30%
Q4 Gross Profit		RMB 98.60 mln
Q4 Operating Expenses		RMB 110.60 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618761136?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618761136","market":"us","top_or_hot":-1,"title":"China's Burning Rock Biotech Q4 net loss narrows as costs fall","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>China's <a href=\"https://laohu8.com/S/BNR\">Burning Rock Biotech</a> Q4 net loss narrows as costs fall</title></head><body><p><span>Overview</span></p><ul><li><p>China precision oncology firm's Q4 revenue was stable year-over-year at RMB126.3 mln</p></li><li><p>Gross profit and gross margin rose, supported by lower costs and higher-margin mix</p></li><li><p>Net loss narrowed sharply on lower operating expenses from cost controls and headcount reduction</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific guidance for future periods</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CENTRAL LAB GROWTH - Revenue from central laboratory business rose 12.1% on higher CanCatch test volumes</p></li><li><p>IN-HOSPITAL EXPANSION - In-hospital business revenue rose 17.3% due to increased sales volume from existing and new partner hospitals</p></li><li><p>PHARMA SERVICES DECLINE - Pharma R&amp;D services revenue fell 27.7% due to decreased testing services for pharma customers from timing of lumpy projects</p></li></ul><p>Company press release: <span>ID:nGNX6VPFB4</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>RMB 126.30 mln</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-RMB 15.40 mln</p></td><td></td></tr><tr><td><p>Q4 Adjusted Gross Margin</p></td><td></td><td><p>80.30%</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>RMB 98.60 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>RMB 110.60 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Burning Rock Biotech Q4 net loss narrows as costs fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Burning Rock Biotech Q4 net loss narrows as costs fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 19:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>China's <a href=\"https://laohu8.com/S/BNR\">Burning Rock Biotech</a> Q4 net loss narrows as costs fall</title></head><body><p><span>Overview</span></p><ul><li><p>China precision oncology firm's Q4 revenue was stable year-over-year at RMB126.3 mln</p></li><li><p>Gross profit and gross margin rose, supported by lower costs and higher-margin mix</p></li><li><p>Net loss narrowed sharply on lower operating expenses from cost controls and headcount reduction</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific guidance for future periods</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CENTRAL LAB GROWTH - Revenue from central laboratory business rose 12.1% on higher CanCatch test volumes</p></li><li><p>IN-HOSPITAL EXPANSION - In-hospital business revenue rose 17.3% due to increased sales volume from existing and new partner hospitals</p></li><li><p>PHARMA SERVICES DECLINE - Pharma R&amp;D services revenue fell 27.7% due to decreased testing services for pharma customers from timing of lumpy projects</p></li></ul><p>Company press release: <span>ID:nGNX6VPFB4</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>RMB 126.30 mln</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-RMB 15.40 mln</p></td><td></td></tr><tr><td><p>Q4 Adjusted Gross Margin</p></td><td></td><td><p>80.30%</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>RMB 98.60 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>RMB 110.60 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石医学","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL1N4000IQ:1","article_id":"2618761136","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618761136","pubTimestamp":1773314155,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"China's Burning Rock Biotech Q4 net loss narrows as costs fallOverviewChina precision oncology firm's Q4 revenue was stable year-over-year at RMB126.3 mlnGross profit and gross margin rose, supported ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学","BK4139":"生物科技"},"translate_title":"随着成本下降，中国燃石生物第四季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":0.9},"content_text":"China's Burning Rock Biotech Q4 net loss narrows as costs fallOverviewChina precision oncology firm's Q4 revenue was stable year-over-year at RMB126.3 mlnGross profit and gross margin rose, supported by lower costs and higher-margin mixNet loss narrowed sharply on lower operating expenses from cost controls and headcount reductionOutlookCompany did not provide specific guidance for future periodsResult DriversCENTRAL LAB GROWTH - Revenue from central laboratory business rose 12.1% on higher CanCatch test volumesIN-HOSPITAL EXPANSION - In-hospital business revenue rose 17.3% due to increased sales volume from existing and new partner hospitalsPHARMA SERVICES DECLINE - Pharma R&D services revenue fell 27.7% due to decreased testing services for pharma customers from timing of lumpy projectsCompany press release: ID:nGNX6VPFB4Key DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueRMB 126.30 mlnQ4 Net Income-RMB 15.40 mlnQ4 Adjusted Gross Margin80.30%Q4 Gross ProfitRMB 98.60 mlnQ4 Operating ExpensesRMB 110.60 mlnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618761136","isCrawlerRequest":true}